Serial Gut Microbiome and Bacterial Gene Markers Changes After Endoscopic Resection of Colorectal Advanced Neoplasia

Launched by CHINESE UNIVERSITY OF HONG KONG · May 16, 2022

Keywords

ClinConnect Summary

This clinical trial is studying how the gut bacteria and specific genetic markers change after patients undergo a procedure called endoscopic resection to remove advanced precancerous growths or early-stage colorectal cancer. The researchers believe that the balance of gut bacteria and certain genetic markers will fluctuate after this treatment, and they want to see if some types of bacteria can help restore a healthy gut environment.

To participate in this trial, individuals must be between 18 and 90 years old and need to have endoscopic resection for conditions like advanced adenomas or early colorectal cancer. Participants will share their health information and undergo tests to monitor their gut microbiome and genetic markers over time. It’s important for potential participants to know that those with certain health conditions, such as severe heart or lung issues, or who are pregnant, will not be eligible for this study. Overall, this research aims to understand how gut health can be affected by medical treatments for colorectal issues.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Subjects require endoscopic resection (e.g. endoscopic mucosal resection or endoscopic submucosal dissection) for advanced adenoma or early-stage colorectal cancer;
• • Aged 18-90 years old;
• • Written informed consent obtained.
• Exclusion Criteria:
• • Absolute contraindications to colonoscopy (e.g. perforation, intestinal obstruction, unstable cardiopulmonary status);
• • Contraindications to endoscopic resection (e.g. active gastrointestinal bleeding, uninterrupted anticoagulation or dual antiplatelets);
• • Known pregnancy or lactation;
• • Advanced comorbid conditions (defined as American Society of Anesthesiologists grade 4 or above);